GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026.

Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
lroth@burnsmc.com

Media Contact:
Real Chemistry
altimmune@realchemistry.com 

This press release was published by a CLEAR® Verified individual.

Source: Altimmune, Inc